Wen-Ting Wang1,2,3, Hua-Yuan Zhu1,2,3, Yu-Jie Wu1,2,3, Yi Xia1,2,3, Jia-Zhu Wu1,2,3, Wei Wu1,2,3, Jin-Hua Liang1,2,3, Li Wang1,2,3, Lei Fan1,2,3, Jian-Yong Li1,2,3, Wei Xu4,5,6. 1. Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China. 2. Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China. 3. Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China. 4. Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China. xuwei10000@hotmail.com. 5. Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China. xuwei10000@hotmail.com. 6. Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China. xuwei10000@hotmail.com.
Abstract
PURPOSE: The aim of this study was to investigate the prognostic significance of the absolute natural killer (NK) cell counts in peripheral blood in patients with chronic lymphocytic leukemia (CLL). METHODS: A total of 273 previously untreated patients with CLL from April 2004 and October 2015 were enrolled into this retrospective study. We analysed the T cell subsets of all patients and figured out the number of NK cells. Comparisons of NK cell count as continuous parameter in different groups were described using Mann-Whitney U test and the Kruskal-Wallis test. Kaplan-Meier method was used to survival analysis, and the Cox proportional hazards models were used for the estimation of prognostic factors. RESULTS: NK cell counts were calculated in 273 therapy-naive CLL patients, and higher number of NK cell was observed in those with Binet stage A/B, ZAP-70 < 20%, normal serum albumin and β2-microglobulin levels. Using a NK cell count cut-off of 0.40 × 109/L, patients with lower NK cell count (< 0.40 × 109/L) had a significantly shorter overall survival (OS) than those with higher NK cell count (≥ 0.40 × 109/L) (P = 0.0014). Multivariate analysis showed that NK cell counts remained its prognostic value. However, the effect of NK cell count on time to treatment was not significant. CONCLUSIONS: Our results suggest that NK cell count is an independent prognostic marker for OS in patients with CLL and NK cell counts ≥ 0.40 × 109/L can routinely be used to identify patients with favorable survival.
PURPOSE: The aim of this study was to investigate the prognostic significance of the absolute natural killer (NK) cell counts in peripheral blood in patients with chronic lymphocytic leukemia (CLL). METHODS: A total of 273 previously untreated patients with CLL from April 2004 and October 2015 were enrolled into this retrospective study. We analysed the T cell subsets of all patients and figured out the number of NK cells. Comparisons of NK cell count as continuous parameter in different groups were described using Mann-Whitney U test and the Kruskal-Wallis test. Kaplan-Meier method was used to survival analysis, and the Cox proportional hazards models were used for the estimation of prognostic factors. RESULTS: NK cell counts were calculated in 273 therapy-naive CLL patients, and higher number of NK cell was observed in those with Binet stage A/B, ZAP-70 < 20%, normal serum albumin and β2-microglobulin levels. Using a NK cell count cut-off of 0.40 × 109/L, patients with lower NK cell count (< 0.40 × 109/L) had a significantly shorter overall survival (OS) than those with higher NK cell count (≥ 0.40 × 109/L) (P = 0.0014). Multivariate analysis showed that NK cell counts remained its prognostic value. However, the effect of NK cell count on time to treatment was not significant. CONCLUSIONS: Our results suggest that NK cell count is an independent prognostic marker for OS in patients with CLL and NK cell counts ≥ 0.40 × 109/L can routinely be used to identify patients with favorable survival.
Authors: Shanique Palmer; Curtis A Hanson; Clive S Zent; Luis F Porrata; Betsy Laplant; Susan M Geyer; Svetomir N Markovic; Timothy G Call; Deborah A Bowen; Diane F Jelinek; Neil E Kay; Tait D Shanafelt Journal: Br J Haematol Date: 2008-04-01 Impact factor: 6.998
Authors: Yi Miao; Yi-Xin Zou; Dan-Ling Gu; Hong-Cheng Zhu; Hua-Yuan Zhu; Li Wang; Jin-Hua Liang; Yi Xia; Jia-Zhu Wu; Chun-Lin Shao; Lei Fan; Zhen Zhang; Wei Xu; Jian-Yong Li Journal: Ann Transl Med Date: 2019-04
Authors: Christian Sordo-Bahamonde; Seila Lorenzo-Herrero; Ana P González-Rodríguez; Ángel R Payer; Esther González-García; Alejandro López-Soto; Segundo Gonzalez Journal: Cancers (Basel) Date: 2021-04-27 Impact factor: 6.639
Authors: Martin Gauthier; Françoise Durrieu; Elodie Martin; Michael Peres; François Vergez; Thomas Filleron; Lucie Obéric; Fontanet Bijou; Anne Quillet Mary; Loic Ysebaert Journal: BMC Cancer Date: 2019-08-14 Impact factor: 4.430
Authors: Paolo Sportoletti; Filomena De Falco; Beatrice Del Papa; Stefano Baldoni; Valerio Guarente; Andrea Marra; Erica Dorillo; Chiara Rompietti; Francesco Maria Adamo; Loredana Ruggeri; Mauro Di Ianni; Emanuela Rosati Journal: Int J Mol Sci Date: 2021-06-22 Impact factor: 5.923